Advaxis to Present at the Noble Financial Sixth Annual Equity Conference – ONTRACK 2010

Chairman/CEO Thomas A. Moore to Discuss Clinical Trial Progress

Place: Hard Rock Hotel, Hollywood, Florida | Date: June 7, 2010 |Time: 9:30 A.M. EDT

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will present at the Noble Financial Sixth Annual Equity Conference at 9:30a.m. EDT on June 7, 2010 at the Hard Rock Hotel in Hollywood, Florida.

The presentation will be webcast – audio, video, PowerPoint - live, and available for viewing at www.advaxis.com or through the Noble Financial websites www.ontrack10.com or www.nobleresearch.com.

For those interested in participating in the webcast, please register at least 10 minutes prior to the start of the presentation to ensure timely access. You will need the SilverLight viewer (a free download from presentation link) to participate. In addition, the webcast and associated collateral material(s) will be archived on the Company’s website for 90 days following the event.

About Noble Financial

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, New Jersey, St Louis and Boca Raton.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
732-545-1084 (FAX)
[email protected]
or
Advaxis, Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  Florida  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.